Use of moclobemide in children with attention deficit hyperactivity disorder
A monoamine oxidase hypothesis for the cause of attention deficit hyperactivity disorder has recently been established (Shekim et al. 1986). To test this, moclobemide, a new and reversible inhibitor of monoamine oxidase-A, was administered to 12 children between the ages of 6 and 13 years, diagnosed...
Gespeichert in:
| Veröffentlicht in: | Psychopharmacologia 1992-02, Vol.106 (S1), p.S134-S136 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S136 |
|---|---|
| container_issue | S1 |
| container_start_page | S134 |
| container_title | Psychopharmacologia |
| container_volume | 106 |
| creator | TROTT, G. E FRIESE, H. J MENZEL, M NISSEN, G |
| description | A monoamine oxidase hypothesis for the cause of attention deficit hyperactivity disorder has recently been established (Shekim et al. 1986). To test this, moclobemide, a new and reversible inhibitor of monoamine oxidase-A, was administered to 12 children between the ages of 6 and 13 years, diagnosed as attention deficit hyperactive according to DSM III-R, in a 4-week study. All had previously discontinued treatment with methylphenidate due to side-effects. A 40% improvement in parental assessment of children's behaviour occurred among those who received moclobemide as outpatients, and a 31% improvement among the five in-patients. There was a general increase in concentration and attention span at the end of the trial, but mood changes and explosive behaviour continued to be present at a low level. Brain mapping after moclobemide treatment showed an overall reduction in frontal lobe delta activity. Moclobemide was well tolerated by these patients, although two complained of mild gastrointestinal disturbances during the first week of therapy. |
| doi_str_mv | 10.1007/BF02246258 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF02246258</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1546129</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-2c8b86b7dc1f54d9f2b7817dcf8198c95a7f8312c4d7b952e797a1e04711c16c3</originalsourceid><addsrcrecordid>eNpFkEtLAzEUhYModaxu3AtZuBJGc_OYZJZarAoFN3Y9ZPKgkXmUJCr994602Ls5XM7HWXwIXQO5B0Lkw9OSUMorKtQJKoAzWlIi6SkqCGGsZCDUObpI6ZNMxxWfoRkIXgGtC7RaJ4dHj_vRdGPr-mAdDgM2m9DZ6Ab8E_IG65zdkMM4YOt8MCHjzW7rojY5fIe8wzakMVoXL9GZ111yV4eco_Xy-WPxWq7eX94Wj6vSMIBcUqNaVbXSGvCC29rTViqYXq-gVqYWWnrFgBpuZVsL6mQtNTjCJYCByrA5utvvmjimFJ1vtjH0Ou4aIM2fkeZoZIJv9vD2q-2dPaJ7BVN_e-h1MrrzUQ8mpH9MgFKUE_YLxh9n8A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Use of moclobemide in children with attention deficit hyperactivity disorder</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>TROTT, G. E ; FRIESE, H. J ; MENZEL, M ; NISSEN, G</creator><creatorcontrib>TROTT, G. E ; FRIESE, H. J ; MENZEL, M ; NISSEN, G</creatorcontrib><description>A monoamine oxidase hypothesis for the cause of attention deficit hyperactivity disorder has recently been established (Shekim et al. 1986). To test this, moclobemide, a new and reversible inhibitor of monoamine oxidase-A, was administered to 12 children between the ages of 6 and 13 years, diagnosed as attention deficit hyperactive according to DSM III-R, in a 4-week study. All had previously discontinued treatment with methylphenidate due to side-effects. A 40% improvement in parental assessment of children's behaviour occurred among those who received moclobemide as outpatients, and a 31% improvement among the five in-patients. There was a general increase in concentration and attention span at the end of the trial, but mood changes and explosive behaviour continued to be present at a low level. Brain mapping after moclobemide treatment showed an overall reduction in frontal lobe delta activity. Moclobemide was well tolerated by these patients, although two complained of mild gastrointestinal disturbances during the first week of therapy.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/BF02246258</identifier><identifier>PMID: 1546129</identifier><identifier>CODEN: PSYPAG</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adolescent ; Adult ; Attention - drug effects ; Attention Deficit Disorder with Hyperactivity - drug therapy ; Attention Deficit Disorder with Hyperactivity - psychology ; Behavior - drug effects ; Benzamides - adverse effects ; Benzamides - therapeutic use ; Biological and medical sciences ; Brain Mapping ; Delta Rhythm - drug effects ; Drug toxicity and drugs side effects treatment ; Electrocardiography ; Electroencephalography - drug effects ; Female ; Humans ; Male ; Medical sciences ; Memory - drug effects ; Moclobemide ; Monoamine Oxidase Inhibitors - adverse effects ; Monoamine Oxidase Inhibitors - therapeutic use ; Pharmacology. Drug treatments ; Toxicity: nervous system and muscle</subject><ispartof>Psychopharmacologia, 1992-02, Vol.106 (S1), p.S134-S136</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-2c8b86b7dc1f54d9f2b7817dcf8198c95a7f8312c4d7b952e797a1e04711c16c3</citedby><cites>FETCH-LOGICAL-c311t-2c8b86b7dc1f54d9f2b7817dcf8198c95a7f8312c4d7b952e797a1e04711c16c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,23909,23910,25118,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5188240$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1546129$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>TROTT, G. E</creatorcontrib><creatorcontrib>FRIESE, H. J</creatorcontrib><creatorcontrib>MENZEL, M</creatorcontrib><creatorcontrib>NISSEN, G</creatorcontrib><title>Use of moclobemide in children with attention deficit hyperactivity disorder</title><title>Psychopharmacologia</title><addtitle>Psychopharmacology (Berl)</addtitle><description>A monoamine oxidase hypothesis for the cause of attention deficit hyperactivity disorder has recently been established (Shekim et al. 1986). To test this, moclobemide, a new and reversible inhibitor of monoamine oxidase-A, was administered to 12 children between the ages of 6 and 13 years, diagnosed as attention deficit hyperactive according to DSM III-R, in a 4-week study. All had previously discontinued treatment with methylphenidate due to side-effects. A 40% improvement in parental assessment of children's behaviour occurred among those who received moclobemide as outpatients, and a 31% improvement among the five in-patients. There was a general increase in concentration and attention span at the end of the trial, but mood changes and explosive behaviour continued to be present at a low level. Brain mapping after moclobemide treatment showed an overall reduction in frontal lobe delta activity. Moclobemide was well tolerated by these patients, although two complained of mild gastrointestinal disturbances during the first week of therapy.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Attention - drug effects</subject><subject>Attention Deficit Disorder with Hyperactivity - drug therapy</subject><subject>Attention Deficit Disorder with Hyperactivity - psychology</subject><subject>Behavior - drug effects</subject><subject>Benzamides - adverse effects</subject><subject>Benzamides - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Brain Mapping</subject><subject>Delta Rhythm - drug effects</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Electrocardiography</subject><subject>Electroencephalography - drug effects</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Memory - drug effects</subject><subject>Moclobemide</subject><subject>Monoamine Oxidase Inhibitors - adverse effects</subject><subject>Monoamine Oxidase Inhibitors - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Toxicity: nervous system and muscle</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtLAzEUhYModaxu3AtZuBJGc_OYZJZarAoFN3Y9ZPKgkXmUJCr994602Ls5XM7HWXwIXQO5B0Lkw9OSUMorKtQJKoAzWlIi6SkqCGGsZCDUObpI6ZNMxxWfoRkIXgGtC7RaJ4dHj_vRdGPr-mAdDgM2m9DZ6Ab8E_IG65zdkMM4YOt8MCHjzW7rojY5fIe8wzakMVoXL9GZ111yV4eco_Xy-WPxWq7eX94Wj6vSMIBcUqNaVbXSGvCC29rTViqYXq-gVqYWWnrFgBpuZVsL6mQtNTjCJYCByrA5utvvmjimFJ1vtjH0Ou4aIM2fkeZoZIJv9vD2q-2dPaJ7BVN_e-h1MrrzUQ8mpH9MgFKUE_YLxh9n8A</recordid><startdate>19920201</startdate><enddate>19920201</enddate><creator>TROTT, G. E</creator><creator>FRIESE, H. J</creator><creator>MENZEL, M</creator><creator>NISSEN, G</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19920201</creationdate><title>Use of moclobemide in children with attention deficit hyperactivity disorder</title><author>TROTT, G. E ; FRIESE, H. J ; MENZEL, M ; NISSEN, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-2c8b86b7dc1f54d9f2b7817dcf8198c95a7f8312c4d7b952e797a1e04711c16c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Attention - drug effects</topic><topic>Attention Deficit Disorder with Hyperactivity - drug therapy</topic><topic>Attention Deficit Disorder with Hyperactivity - psychology</topic><topic>Behavior - drug effects</topic><topic>Benzamides - adverse effects</topic><topic>Benzamides - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Brain Mapping</topic><topic>Delta Rhythm - drug effects</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Electrocardiography</topic><topic>Electroencephalography - drug effects</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Memory - drug effects</topic><topic>Moclobemide</topic><topic>Monoamine Oxidase Inhibitors - adverse effects</topic><topic>Monoamine Oxidase Inhibitors - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Toxicity: nervous system and muscle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>TROTT, G. E</creatorcontrib><creatorcontrib>FRIESE, H. J</creatorcontrib><creatorcontrib>MENZEL, M</creatorcontrib><creatorcontrib>NISSEN, G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Psychopharmacologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>TROTT, G. E</au><au>FRIESE, H. J</au><au>MENZEL, M</au><au>NISSEN, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of moclobemide in children with attention deficit hyperactivity disorder</atitle><jtitle>Psychopharmacologia</jtitle><addtitle>Psychopharmacology (Berl)</addtitle><date>1992-02-01</date><risdate>1992</risdate><volume>106</volume><issue>S1</issue><spage>S134</spage><epage>S136</epage><pages>S134-S136</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><coden>PSYPAG</coden><abstract>A monoamine oxidase hypothesis for the cause of attention deficit hyperactivity disorder has recently been established (Shekim et al. 1986). To test this, moclobemide, a new and reversible inhibitor of monoamine oxidase-A, was administered to 12 children between the ages of 6 and 13 years, diagnosed as attention deficit hyperactive according to DSM III-R, in a 4-week study. All had previously discontinued treatment with methylphenidate due to side-effects. A 40% improvement in parental assessment of children's behaviour occurred among those who received moclobemide as outpatients, and a 31% improvement among the five in-patients. There was a general increase in concentration and attention span at the end of the trial, but mood changes and explosive behaviour continued to be present at a low level. Brain mapping after moclobemide treatment showed an overall reduction in frontal lobe delta activity. Moclobemide was well tolerated by these patients, although two complained of mild gastrointestinal disturbances during the first week of therapy.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>1546129</pmid><doi>10.1007/BF02246258</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0033-3158 |
| ispartof | Psychopharmacologia, 1992-02, Vol.106 (S1), p.S134-S136 |
| issn | 0033-3158 1432-2072 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF02246258 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adolescent Adult Attention - drug effects Attention Deficit Disorder with Hyperactivity - drug therapy Attention Deficit Disorder with Hyperactivity - psychology Behavior - drug effects Benzamides - adverse effects Benzamides - therapeutic use Biological and medical sciences Brain Mapping Delta Rhythm - drug effects Drug toxicity and drugs side effects treatment Electrocardiography Electroencephalography - drug effects Female Humans Male Medical sciences Memory - drug effects Moclobemide Monoamine Oxidase Inhibitors - adverse effects Monoamine Oxidase Inhibitors - therapeutic use Pharmacology. Drug treatments Toxicity: nervous system and muscle |
| title | Use of moclobemide in children with attention deficit hyperactivity disorder |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T06%3A36%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20moclobemide%20in%20children%20with%20attention%20deficit%20hyperactivity%20disorder&rft.jtitle=Psychopharmacologia&rft.au=TROTT,%20G.%20E&rft.date=1992-02-01&rft.volume=106&rft.issue=S1&rft.spage=S134&rft.epage=S136&rft.pages=S134-S136&rft.issn=0033-3158&rft.eissn=1432-2072&rft.coden=PSYPAG&rft_id=info:doi/10.1007/BF02246258&rft_dat=%3Cpubmed_cross%3E1546129%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/1546129&rfr_iscdi=true |